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Abstract
Anaplastic thyroid carcinoma (ATC) is an extremely aggressive thyroid cancer subtype, 
refractory to the current medical treatment. Among various epigenetic anticancer drugs, 
bromodomain and extra-terminal inhibitors (BETis) are considered to be an appealing 
novel class of compounds. BETi target the bromodomain and extra-terminal of BET 
proteins that act as regulators of gene transcription, interacting with histone acetyl 
groups. The goal of this study is to delineate which pathway underlies the biological 
effects derived from BET inhibition, in order to find new potential therapeutic targets 
in ATC. We investigated the effects of BET inhibition on two human anaplastic thyroid 
cancer-derived cell lines (FRO and SW1736). The treatment with two BETis, JQ1 and 
I-BET762, decreased cell viability, reduced cell cycle S-phase, and determined cell death. 
In order to find BETi effectors, FRO and SW1736 were subjected to a global transcriptome 
analysis after JQ1 treatment. A significant portion of deregulated genes belongs to cell 
cycle regulators. Among them, MCM5 was decreased at both mRNA and protein levels 
in both tested cell lines. Chromatin immunoprecipitation (ChIP) experiments indicate 
that MCM5 is directly bound by the BET protein BRD4. MCM5 silencing reduced cell 
proliferation, thus underlining its involvement in the block of proliferation induced by 
BETis. Furthermore, MCM5 immunohistochemical evaluation in human thyroid tumor 
tissues demonstrated its overexpression in several papillary thyroid carcinomas and in 
all ATCs. MCM5 was also overexpressed in a murine model of ATC, and JQ1 treatment 
reduced Mcm5 mRNA expression in two murine ATC cell lines. Thus, MCM5 could 
represent a new target in the therapeutic approach against ATC.
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Introduction
Thyroid cancers are the most widespread malignancies 
of the endocrine system and represent approximately 
1–1.5% of all tumor-related diseases. The overall 5-year 
survival of these tumors is approximately 85–90%, 
with the highest mortality rate reported for poorly 
differentiated histotypes (Durante et al. 2006, Patel & 
Shaha 2014). Anaplastic thyroid carcinomas (ATCs), which 
are wholly or partially composed of undifferentiated cells 
arising from thyroid follicular epithelium, represent the 
least common but most lethal thyroid cancer subtype. 
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Indeed, they are characterized by genetic and epigenetic 
aberrations that make them unresponsive to treatments 
based on radioiodine administration (Arturi et al. 2000, 
Schlumberger et al. 2007, Perri et al. 2011, Elisei 2012). 
Thus, innovative approaches for ATC treatment are 
required.
The term ‘epigenetics’ is commonly used to describe 
the study of hereditable changes in gene expression that 
are independent from alteration in the underlying DNA 
sequence. As aberrant gene expression is an essential 
characteristic that distinguishes neoplastic cells from 
normal ones, compounds able to target epigenetic 
alterations are becoming increasingly appealing 
for cancer treatment. Most of these molecules act 
on epigenetic ‘writers’ or ‘erasers’, that is, enzymes 
regulating DNA or histone covalent modifications. 
Notably, compounds targeting enzymes involved in 
DNA methylation and histone acetylation have been 
greatly investigated in several experimental models 
of solid tumors, including thyroid cancer (Puppin et 
al. 2005, Russo et al. 2013). Several other chromatin 
regulators, instead, act as ‘readers’: they possess peculiar 
domains that are able to interact with nucleosome 
covalent modifications and respond to upstream signal 
cascades to control gene expression (Dawson et al. 
2012). A rising class of compounds that are able to target 
chromatin readers is called BET inhibitors (BETis). BET is 
the acronym of bromodomain and extra-terminal family 
of proteins (Nicodeme et al. 2010). The mammalian 
BET protein family includes four members: BRD2, 
BRD3, and BRD4, which are ubiquitously expressed, 
and BRDT, whose expression is confined to germ cells. 
These proteins possess a tandem bromodomain at the 
N-terminal region, by which they interact with histone 
acetyl-lysines in order to control gene transcription and 
cell proliferation (Chiang 2009). Due to the relevance 
of BET proteins, several inhibitors have been recently 
developed (Filippakopoulos et al. 2010, Nicodeme 
et al. 2010). BETis hinder proliferation of a wide range 
of hematopoietic malignant cell lines and nuclear 
protein in testis (NUT) midline carcinoma-derived cells 
(Filippakopoulos et al. 2010, Zuber et al. 2011). The use of 
BETis, as well as the use of other epigenetic compounds, 
might be a complicate issue in cancer treatment because 
these drugs act on a large spectrum of genes (Falahi et 
al. 2015). However, the antiproliferative outcome could 
be reasonably due to the deregulation of only a small 
subset of genes. For instance, repression of the c-MYC 
oncogene seems to play a major role in mediating the 
effects of BETis in leukemic cells (Ott et al. 2012). Thus, 
an attractive approach to study epigenetic compounds is 
to define their critical effector genes. For this purpose, in 
this study we investigated the effects of BET inhibition 
in two human ATC cell lines, analyzing the modulation 
of their global gene expression profiles. By using this 
approach, we propose MCM5 as a potential new target 
for ATC treatment.
Materials and methods
Human and murine cell lines
FRO (purchased from the European Collection of Cell 
Cultures, Salisbury, UK) and SW1736 (obtained from 
Cell Lines Service GmbH, Eppelheim, Germany) are 
human cell lines derived from ATC, both harboring 
a BRAF V600E mutation (Schweppe et al. 2008, Pilli 
et al. 2009). Both cell lines have been tested for being 
mycoplasma free and authenticated by short tandem 
repeats (STR) analysis to be appropriate cell lines of 
thyroid cancer origin. FRO and SW1736 were grown 
in DMEM medium (EuroClone, Milan, Italy) and RPMI 
1640 medium (EuroClone), respectively, supplemented 
with 10% fetal bovine serum (Gibco Invitrogen, Milan, 
Italy), 2 mM l-glutamine (EuroClone), and 50 mg/mL 
gentamicin (Gibco Invitrogen), in a humidified 
incubator (5% CO2 in air at 37 °C). Cultured cells were 
treated with vehicle (DMSO, Sigma-Aldrich, St Louis, 
MO, USA) or the following agents: JQ1 (50 nM–10 μM 
in DMSO) (Cayman Chemical, Ann Arbor, MI, USA) and 
I-BET762 (50 nM–10 μM in DMSO) (Merck Millipore). 
T4888M and T3531L are ATC cell lines derived from 
tumors developed by [Pten, Tp53]thyr–/– mice (Antico 
Arciuch et al. 2011). Cells were grown in DMEM 
supplemented with 10% FBS.
Animals
[Pten, Tp53]thyr–/– and Ptenthyr–/– mice have been as 
described previously (Yeager et al. 2007, Antico Arciuch 
et al. 2010,  2011). The animals were housed in the Albert 
Einstein College of Medicine animal facility under specific 
pathogen-free conditions.
Cell viability and apoptosis
To test cell viability, an MTT assay was performed as 
described previously (Baldan et al. 2014). Briefly, 5000 
cells were seeded onto 96-well plates. On the next day, the 
growth medium was replaced with vehicle-treated medium 
(NT, untreated cultures) or with medium containing JQ1 
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or I-BET762; plates were incubated for 0, 24, 48, and 
72 h. All experiments were run in quadruplicate and cell 
viability was expressed as a percentage relative to baseline 
samples (T0). The percentage of cell viability assessed by 
MTT assay was used to determine EC50 concentrations 
from dose–response curves after 72 h treatment.
Caspase 3/7 activity was measured as a marker 
of apoptosis using the Apo-ONE Homogeneous 
Caspase-3/7 Assay Kit (Promega, Milan, Italy) according 
to the manufacturer’s protocol. Five thousand cells were 
seeded onto 96-well plates. On the next day, the growth 
medium was replaced with vehicle-treated medium (NT, 
untreated cultures) or medium containing JQ1 5 μM or 
I-BET762 5 μM; the plates were incubated for 48 h. All 
experimental points were run in triplicate, and apoptosis 
levels were expressed as a percentage relative to baseline 
samples (NT).
Cell cycle analysis
Cell cycle was determined by fluorescence-activated cell-
sorting (FACS) analysis of DNA content. Briefly, FRO 
and SW1736 cells were collected after a 24, 48, and 72 h 
treatment with either JQ1 or vehicle (NT); the cells were 
fixed in cold ethanol 70% and stained with propidium 
iodide solution containing RNase and Triton-X100. Flow 
cytometric analysis was performed on a FACSCalibur 
(Becton Dickinson, Franklin Lakes, NY, USA) using 
ModFit LT analysis software (Verity Software House, Inc., 
Topsham, ME, USA). A minimum of 20,000 cells was 
analyzed for each sample. All experiments were run in 
triplicate.
High-throughput RNA sequencing and analysis
About 1.5 μg of good-quality RNA (RNA Integrity 
Number >7) was used as a starting material for preparation 
of library using the Illumina mRNASeq Sample Prep 
Kit v2.0, following the manufacturer’s instructions 
(Illumnina, San Diego, CA, USA). The poly-A mRNA 
was fragmented for 1.5 min at 94°C, and all purification 
steps were performed by using 1X Agencourt AMPure 
XP beads (Beckman Coulter, Brea, CA, USA). Quality 
and quantity of each library were assessed by using an 
Agilent 2100 Bioanalyzer High Sensitivity and Qubit DNA 
High Sensitivity (Invitrogen). The libraries were pooled 
together and the obtained pool was checked on an Agilent 
Bioanalyzer 2100 in order to determine the molarity. 
Single-read sequencing was performed on the HiSeq2000 
(Illumina, San Diego, CA, USA) generating 50-base reads. 
The CASAVA 1.8.2 version of the Illumina pipeline was 
used for image analysis, base calling, and demultiplexing. 
Reads were first trimmed in order to remove lower base 
quality data with ERNE (extended randomized numerical 
aligner) (Vezzi et al. 2012), and adapter sequences were 
removed with cutadapt (https://pypi.python.org/pypi/
cutadapt/1.3). TopHat (Trapnell et al. 2012) was used 
for mapping and annotation on the HG19 reference 
sequence. Differential gene expression analysis was 
performed according to the experimental design using 
Cufflinks (Trapnell et al. 2012).
Gene expression assays
Total RNA from human cell lines, treated with either JQ1 
5 μM or vehicle, was extracted with the RNeasy Mini Kit 
(Qiagen) according to manufacturer’s instructions. About 
500 ng of total RNA were reverse transcribed to cDNA 
using random exaprimers and MMLV reverse transcriptase 
(Life Technologies). Real-time PCRs were performed using 
Platinum SYBR Green qPCR SuperMix (Life Technologies) 
with the ABI Prism 7300 Sequence Detection Systems 
(Applied Biosystems). The ∆∆CT method, by means 
of the SDS software (Applied Biosystems), was used to 
calculate mRNA levels. Oligonucleotide primers for 
MCM5 (forward, 5ʹ-GATCCTGGCATTTTCTACAG-3ʹ; 
reverse, 5ʹ-CCCTGTATTTGAAGGTGAAG-3ʹ) and β-actin 
(forward, 5ʹ-TTGTTACAGGAAGTCCCTTGCC-3ʹ; reverse, 
5ʹ-ATGCTATCACCTCCCCTGTGTG-3ʹ) were purchased 
from Sigma-Aldrich.
Total mouse RNA (treated with either 0.5 μM or 
vehicle) was extracted with Trizol and reverse transcribed 
using the Maxima First Strand cDNA Synthesis Kit 
(Thermo Scientific). qRT-PCR was performed on a 
StepOnePlus apparatus using SYBR Green PCR Master 
Mix (Applied Biosystems) and custom-designed primers 
(forward, 5ʹ-CAGAGGCGATTCAAGGAGTTC-3ʹ; reverse, 
5ʹ-CGATCCAGTATTCACCCAGGT-3ʹ). Each sample was 
run in triplicate and 18S was used to control for input 
RNA. Data analysis was based on the CT method, and 
experiments were repeated at least three times using at 
least two independent organ and cell pools.
Chromatin immunoprecipitation
The chromatin immunoprecipitation (ChIP) assay was 
performed as described previously (Baldan et al. 2015). For 
immunoprecipitation, samples were incubated with 10 μg 
of rabbit polyclonal anti-BRD4 (Active Motif, Carlsbad, CA, 
USA) or Rabbit IgG (Millipore) as negative control (NC). 
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After incubation with Dynabeads Protein A (Invitrogen), 
washing, and elution, the DNA was extracted with 
phenol/chloroform, and the aqueous phase recovered and 
precipitated. The extracted DNA was used as a template in 
qPCR with the following primers: MCM5 Forward Primer 
(CCTGTTCTGGCCGTTTGTTC), MCM5 Reverse Primer 
(GATCGTCGAATCCCGACATG); NCR Forward Primer 
(TGCTGTTACTTTTTACAGGGAGTT), NCR Reverse Primer 
(TTTGAGCAAAATGTTGAAAACAA). Fold enrichment 
was, then, calculated as signal over background (IgG). 
Data are representative of three different experiments.
RNA silencing
For transient silencing of endogenous MCM5, the 
TriFECTa RNAi Kit (Integrated DNA Technologies, Inc., 
Coralville, IA, USA) was used. A ‘universal’ NC duplex 
that targets a site that is absent from human, mouse, 
and rat genomes was used. siRNA oligonucleotides were 
transfected at a concentration of 5 nM using DharmaFECT 
Transfection reagent (Thermo Scientific), according to the 
manufacturer’s instructions. The day before transfection, 
cells were plated in antibiotics-free medium and harvested 
72 h after transfection. The gene-silencing efficiency was 
evaluated by mRNA and protein level analysis.
Annexin V assay
In other to test the percentage of viable/apoptotic 
cells after MCM5 silencing, an Annexin V assay was 
performed. Briefly, cells were washed with cold PBS, 
transferred to a polystyrene round-bottomed flow tube 
(Falcon; Becton Dickinson), and resuspended in 195 μL 
of 1 binding buffer (BB 10 mM; HEPES/NaOH, pH 7.4, 
140 mM NaCl, and 2.5 mM CaCl2). Five microliter of 
Fluorescein-conjugated Annexin V (Annexin V-FITC; 
Bender Med Systems, Vienna, Austria) was added and 
samples were incubated for 10 min at room temperature. 
After washing, cells were resuspended in 190 μL of BB in 
which 10 μL of propidium iodide stock solution (final 
concentration 1 μg/mL) was added. Flow cytometric 
analysis was done on CyAN, Dako Cytomation using 
Summit software (flow cytometer; Beckman Coulter). 
Forward scatter and side scatter were acquired in a 
linear mode. FITC and PI fluorescent signals derived 
from 488 nM excitation were detected in a logarithmic 
mode at FL1/PMT3 and FL2/PMT4, with FITC 530/30 nM 
filters and PI 585/42 nM filters, respectively, and a FL1/2 
560 nM shortpass dichroic filter. Signals for forward and 
side scatter and fluorescence were collected for 104 cells 
using the forward light scatter parameter as the master 
signal. Data are expressed as mean fluorescence intensity 
(FI) values. All experiments were run in triplicate.
MCM5 overexpression
To overexpress MCM5 protein, we purchased the 
TrueClone MCM5 cDNA cloned in pCMV6-AC, which 
contains a full open reading frame of the human MCM5 
gene (Origene, Rockville, MD, USA). The overexpression 
vector was transfected with Turbofect reagent (Fisher 
Scientific S.A.S., Illkirch, France) at 2 μL per well. pCMV 
empty vector was used as NC. Once we verified the 
overexpression by immuonoblotting, we performed 
a rescue experiment, in order to verify the direct 
involvement of MCM5 in JQ1 mechanism of action. 
Cells were transfected with pCMV-MCM5 or NC and 
exposed to 5 μM JQ1 or vehicle for 48 h. Cell viability was 
evaluated by MTT assay, as described previously.
Protein extraction and Western blot
Total protein extraction was performed as described 
previously (Passon et al. 2012). Briefly, FRO and SW1736 
cells, incubated in vehicle-treated medium (NT, untreated 
cultures) or with JQ1 5 μM, were harvested by scraping 
and lysed with total lysis buffer (Tris–HCl 50 mM pH8, 
NaCl 120 mM, EDTA 5 mM, Triton 1%, NP40 1%, protease 
inhibitors). For subcellular fractionation, pellets were 
resuspended in buffer A (10 mM Tris–HCl (pH 7.5), 1.5 mM 
MgCl2, and 10 mM KCl supplemented with 1 × protease 
inhibitor cocktail, 0.5 mM PMSF, 1 mM NaF, and 1 mM 
Na3VO4) and centrifugated at 2000 g for 10 min at 4°C. 
For nuclear extracts collection, pellets were resuspended 
in buffer B (20 mM Tris–HCl (pH 7.5), 0.42 M KCl, 1.5 mM 
MgCl2, 20% (vol/vol) glycerol supplemented with 1 × 
protease inhibitor cocktail, 0.5 mM PMSF, 1 mM NaF, and 
1 mM Na3VO4) and centrifuged at 15,000 g for 30 min 
at 4°C. For western blotting analysis, proteins were 
electrophoresed on 10% SDS–PAGE and then transferred 
to nitrocellulose membranes, which were saturated 
with 5% nonfat dry milk in PBS/0.1% Tween 20. The 
membranes were then incubated overnight with rabbit 
polyclonal anti-BRD4 antibody 1:1000 (Active Motif), 
rabbit anti-lamin-β1 antibody 1:1000 (Abcam), rabbit 
polyclonal anti-MCM5 antibody 1:250 (Sigma-Aldrich), 
or rabbit anti-β-actin antibody 1:1000 (Abcam). The 
next day, membranes were incubated for 2 h with 
anti-rabbit immunoglobulin coupled to peroxidase 
1:4000 (Sigma-Aldrich). The blots were developed using 
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Uvitec Alliance LD (UVItec Limited, Cambridge, UK) with 
the SuperSignal Technology (Thermo Fisher Scientific).
Human tissues and immunohistochemistry
A series of 12 normal thyroid glands (NTs), 25 follicular 
adenomas (FAs), 23 follicular thyroid carcinomas (FTCs), 
36 papillary thyroid carcinomas (PTCs), and eight ATCs 
were selected from the files of the Institution of Anatomic 
Pathology of the University of Udine (Udine, Italy), and 
the most representative block of each lesion was retrieved 
from the archive. Representative tumor-bearing areas 
were selected and a tissue microarray was constructed. 
All samples were diagnosed by referral pathologists 
of the institution and then reviewed by a single 
experienced pathologist, thus including only patients 
with a confirmed diagnosis. Briefly, 5 μM formalin-fixed 
paraffin tissue sections mounted on SuperFrost Plus slides 
(Menzel-Gläser, Braunschweig, Germany) were placed in 
the PT Link pre-treatment module (DAKO A/S, Glostrup, 
Denmark), which performs automatically the entire pre-
treatment process of de-paraffinization, rehydration, 
and epitope retrieval using the Low pH Target Retrieval 
Solution (0.001 M citrate buffer pH 6.0) at 98°C for 
40 min from DAKO. Endogenous peroxidase activity 
was blocked by incubation using the peroxidase block 
solution (DAKO) for 5 min. Primary rabbit polyclonal 
antiserum to MCM5 (Sigma-Aldrich) diluted 1:1000 was 
applied and incubated for 60 min at room temperature. 
After washing, the slides were incubated with the 
DAKO EnVision FLEX System (DAKO) according to the 
manufacturer’s guidelines. For reaction visualization, 
3,3'-diaminobenzidine tetrahydrochloride was used 
as chromogen. The sections were counterstained with 
Mayer’s hematoxylin. Using light microscopy, the 
entire section was scanned at high-power magnification 
(400×) and nuclear immunostaining was evaluated semi-
quantitatively as percentage of positive cells. Staining 
intensity was scored as light, moderate, and strong. A 
final score was then calculated by multiplying the percent 
staining by the intensity level.
Statistical analysis
mRNA and protein levels, cell viability, and apoptosis 
levels were expressed as means ± s.d., and significances 
were determined by a one-way ANOVA followed by 
Dunnett’s test performed with GraphPAD Software 
for Science. *P value < 0.05 was considered to be 
statistically significant.
Results
Biological effects of BETis on ATC cells
In a first set of experiments, we evaluated the sensitivity 
of two human anaplastic thyroid cancer cell lines (FRO 
and SW1736) to BETis. As shown in Fig.  1, incubation 
either with JQ1 (Fig. 1A) or I-BET762 (Fig. 1B) significantly 
reduced FRO and SW1736 cell viability at different time 
points. Relying on data obtained, for further experiments, 
we decided to use the median effective dose of 5 μM; 
i.e., the dose required to achieve 50% of the desired response 
in 50% of the population. To assess whether the decrease in 
cell viability was due to an increase of apoptotic cell death, 
caspase 3/7 levels were measured after 48 h treatment. 
Administration of JQ1 increased caspase levels in both 
cell lines in a quite striking manner, whereas I-BET762 
treatment showed a less pronounced effect (Fig.  1C). 
In order to verify whether a 48 h I-BET762 treatment 
displayed a caspase-independent cell death, we perform a 
western blotting analysis of PARP. PARP is known to be 
a substrate for several proteins such as caspases, calpains, 
and cathepsins; it produces several specific cleavage 
fragments that resemble signature patterns of different 
cell death programs (Gobeil et al. 2001; Chaitanya et al. 
2010). As shown in Supplementary Fig. 2 see section on 
supplementary data given at the end of this article (Fig. 2A 
and B), ATC cells showed a marked increase of both 
apoptotic- and necrotic-specific cleaved-PARP. We, then, 
corroborated the BET inhibition effects on cell viability 
and cell death in 8505c cells, a third anaplastic thyroid 
cell line (Supplementary Fig.  3). Moreover, we used a 
third BETi: I-BET151. This latter is a pan-BETi having a 
slight different chemical structure compared to I-BET762. 
I-BET151 reduced cell viability similarly to I-BET762 
(Supplementary Fig. 1A and B, and Supplementary Fig. 3). 
Hereinafter, we decided to proceed in our investigation 
with JQ1-treatment only, as it revealed to be the most 
effective drug, in terms of biological effects, in both cell 
lines. A FACS analysis of the cell cycle was then performed 
on both cell lines treated with 5 μM JQ1 for 24, 48, and 
72 h. JQ1-treatment significantly increased the proportion 
of cells arrested in G0/G1 at each analyzed time point 
(Fig. 1D).
Differential gene expression after BET inhibition
To identify potential molecular targets connected to 
BET inhibition, we performed a high-throughput RNA 
sequencing (RNA-seq) analysis on both FRO and SW1736 
cells treated with 5 μM JQ1 or vehicle for 24 h. To assess 
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the transcriptional changes induced by BET inhibition, 
a comparison between cells treated with JQ1 or vehicle 
was performed. Heat maps representing each analyzed 
condition are shown in Fig. 2A. Expression of 14,199 and 
13,013 genes was detected in FRO and SW1736 cell lines, 
respectively. Vehicle-treated (NT) FRO and SW1736 cells 
showed a quite different mRNA profile. After filtering 
low quantity reads, results showed that approximately 
2000 genes were differentially expressed after JQ1 
treatment either in FRO or SW1736 cells (at a log2 fold 
change >2) (Supplementary Tables 1 and 2, see section on 
supplementary data given at the end of this article). Among 
them, 768 genes were significantly upregulated and 1229 
were downregulated in response to JQ1 treatment (Fig. 2B). 
Venn diagrams showed that the majority of altered genes 
was specific for each cell line, which likely underlies the 
differential mRNA profile observed with vehicle treatment. 
However, there was a core set of 288 genes commonly 
affected by JQ1 treatment in both cell lines, most of 
which decreased their expression (n = 213). RNA-seq data, 
then, were confirmed by qPCR (Supplementary Fig.  4). 
The shared top 20 differentially expressed genes (Table 1) 
were then subjected to Ingenuity Pathway Analysis in 
order to outline which pathways were mostly affected 
by JQ1 treatment. Various signaling cascades turned 
out to be modified by BETis treatment: regulation of 
DNA and metabolic processes proved out to be the 
most deregulated one (Supplementary Table  3). The 
RNA-seq analysis identified a large number of JQ1 
putative targets, primarily in cell cycle-linked pathways. 
Figure 1
BETis administration decreases proliferation and 
survival of ATC cell lines. (A and B) FRO and 
SW1736 were exposed to JQ1 or I-BET762 
different doses (rising from 50 nM to 10 μM). Cell 
viability was determined by the MTT assay after 
0, 24, 48, and 72 h and expressed as a percentage 
of baseline samples (T0). All samples were run in 
quadruplicate. (C) Apoptosis levels were 
evaluated 48 h after treatment with either 5 μM 
BETis or vehicle (NT). Caspase 3/7 levels were 
normalized to the vehicle-treated group. 
Temozolomide (500 μM), a chemotherapy drug, 
was used as a positive control for apoptosis. Each 
sample was run in triplicate. *P < 0.05, 
***P < 0.001, ****P < 0.0001 by ANOVA test. (D) 
FRO and SW1736 cell cycle distribution was 
determined after 5 μM JQ1 or vehicle 
administration. Cells were collected after 24, 48, 
and 72 h treatments. Data are representative of 
three independent experiments.
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These data are consistent with Da Costa’s findings in 
leukemia cells (Da Costa et al. 2013). Several studies have 
proposed a possible role of c-MYC downregulation as a 
major mechanism of action of BETis (Alderton 2011, Zuber 
et al. 2011). Our RNA-seq data show that this oncogene is 
not a critical factor in JQ1-mediated effects in ATC cells, 
because JQ1 treatment did not significantly affect c-MYC 
expression in neither of the two cell lines (Supplementary 
Fig. 4). BETis, however, modified the expression of several 
cell cycle regulators such as RB proteins, E2F transcription 
factors, and CDK inhibitors (Supplementary Table 4).
BETis effects on MCM5
Considering that cell cycle regulatory genes were the 
most affected by JQ1 treatment, we focused on MCM5, 
one of the top 20 downregulated genes, which is 
known to be involved in G1/S cell cycle transition, 
Figure 2
Gene expression modifications in ATC JQ1-treated cell lines. (A) Heat 
maps showing the hierarchical clustering of mRNA targets in FRO and 
SW1736 cell lines (n = 1997). Cells were treated with either 5 μM JQ1 or 
vehicle for 24 h. (B) Venn diagrams representing the comparison of both 
upregulated (left) and downregulated (right) genes between FRO and 
SW1736 cell lines after RNA-seq data analysis. Purple gene clusters 
represent shared modified genes between FRO and SW1736 cell lines.
Figure 3
Downregulation of MCM5 in human and murine ATC cell lines after JQ1 
treatment. (A) FRO and SW1736 cells were treated either with 5 μM JQ1 
or vehicle for 24 h, and MCM5 mRNA expression was evaluated by qPCR. 
All samples were run in triplicate. Vehicle-treated (NT) FRO cells were 
arbitrarily set at 1.0 and mRNA levels are expressed as relative expression 
values. (B) FRO and SW1736 were treated with either 5 μM JQ1 or vehicle 
for 72 h, and MCM5 protein levels were detected by western blotting. (C) 
Densitometric analysis of MCM5 protein levels in ATC cells after 5 μM JQ1 
or vehicle treatment. (D) T4888M and T3531L cells were treated with 
either 0.5 μM JQ1 or vehicle for 72 h, and Mcm5 mRNA expression was 
evaluated by qPCR. All samples were run in triplicate. Vehicle-treated 
(NT) T4888M cells were arbitrarily set at 1.0 and mRNA levels are 
expressed as relative expression values. Results are shown as mean ± s.d. 
***P < 0.001, ****P < 0.0001 by ANOVA test. Data are representative of 
three independent experiments.
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coordinating origin activation and replication fork 
progression. MCM5 belongs to the minichromosome 
maintenance complex family, which has been associated 
with the highly proliferative phenotype of ATC (Guida 
et al. 2005). Several studies have established that MCM5 
protein level is a good diagnostic marker of malignancy 
for bladder, esophageal, and gastric cancers (Kebebew 
et al. 2006). After confirming RNA-seq data on mRNA levels 
(Fig.  3A), we evaluated whether a 5 μM JQ1 treatment 
significantly altered MCM5 protein levels in FRO and 
SW1736 cells (Fig. 3B). After 72 h incubation with JQ1, a 
significant reduction in MCM5 protein levels was observed 
(Fig.  3C). To extend and further validate this finding, 
we used two murine ATC cell lines derived from tumors 
developed by a genetically defined mouse model of ATC. 
Treatment of both lines with 0.5 μM JQ1 for 72 h resulted 
in a significant downregulation of Mcm5 RNA (Fig. 3D). To 
evaluate whether MCM5 is a direct target of BRD4, which 
is the BET protein whose activity is inhibited by JQ1, we 
performed a ChIP-qPCR analysis in FRO and SW1736 
cells. We first evaluated if the two cell lines expressed 
comparable BRD4 protein levels (Fig. 4A). After the ChIP 
assay, we observed an average five-fold MCM5 enrichment 
in the BRD4 immunoprecipitate compared with the IgG 
one. To confirm specificity, an intergenic region has been 
used as an NC for BRD4 binding (Fig.  4B). In order to 
test the biological relevance of MCM5 gene repression 
upon BET inhibition, an RNA interference analysis was 
performed. MCM5 gene expression was silenced both 
in FRO and in SW1736 cells, and immunoblot analysis 
Figure 4
MCM5 is directly involved in BETis effects in 
human ATC cell lines. (A) BRD4 protein 
expression in ATC cell lines. (B) Chromatin was 
isolated from ATC cell lines and 
immunoprecipitated with BRD4 or IgG 
antibodies. MCM5 DNA was amplified using 
promoter-specific primers and analyzed by 
qPCR. All samples were run in triplicate. IgG 
immunoprecipitate was arbitrarily set at 1.0 and 
the enrichment was expressed as a relative 
expression value. An intergenic region (NCR) 
was used as an NC for BRD4 binding. (C) FRO 
and SW1736 cells were treated with 
nontargeting siRNA (NC) or three different 
siRNA sequences specific to MCM5 (5 nM). Cells 
were collected after 72 h treatment and MCM5 
protein levels were analyzed. (D) FRO and 
SW1736 were exposed to either siRNA targeting 
MCM5 or NC for 72 h and apoptosis levels was 
analyzed by Annexin V staining. (E) FRO and 
SW1736 cells were treated with pCMV empty 
vector (NC) or pCMV vector specific for MCM5 
(1.3 μg). Cells were collected after 48 h treatment 
and MCM5 protein levels were analyzed. (F) FRO 
and SW1736 were treated with 0.01 μg 
p-CMV-MCM5 or empty vector and exposed to 
5 μM JQ1 or vehicle. Cell viability was 
determined by the MTT assay after 48 h. NT was 
arbitrarily set at 100 and cell viability was 
expressed as a relative expression value. All 
samples were run in quadruplicate. Results are 
shown as mean ± s.d. ***P < 0.001, 
****P < 0.0001 by ANOVA test. Data are 
representative of three independent 
experiments.
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revealed an almost total abolishment of endogenous 
MCM5 protein level with siRNA#2 treatment (Fig.  4C). 
Furthermore, MCM5 silencing, especially with siRNA#2, 
significantly decreased cell viability (P < 0.001), increasing 
the percentage of apoptotic cells after Annexin V 
staining compared with NC (Fig. 4D). Similarly, to what 
we observed treating cells with JQ1, this outcome was 
more pronounced in SW1736 than in FRO cells. To 
further prove that MCM5 is directly involved in the cell 
viability decrease after 5 μM JQ1 treatment, we performed 
a rescue experiment. FRO and SW1736 cells were treated 
with pCMV-MCM5 or NC and exposed to JQ1 for 48 h. 
As shown in Fig.  4E, MCM5 protein overexpression 
partially rescued its protein levels in JQ1-treated cells. To 
validate that this phenomenon is associated with a cell 
viability rescue, an MTT assay was performed. FRO and 
SW1736 cells overexpressing MCM5 displayed a slight 
but significant reduction (10% on average) of JQ1 effects 
when assessing cell viability (Fig.  4F). This mild rescue 
could be explained by the multitarget activity of BETis, 
whose effects are mediated by a remarkable number of 
actors, as we showed in our RNA-seq analysis (Fig. 2).
In vivo MCM5-level evaluation
Our data underline the relevance of MCM5 in thyroid 
cancer cell proliferation. Thus, MCM5 expression was 
evaluated in a panel of 12 NTs, 25 FAs, 23 FTCs, 36 PTCs, 
and 8 ATCs. Representative images of MCM5 staining are 
shown in  Fig. 5A. MCM5 was faintly expressed in normal 
thyroid tissue and FAs. PTCs showed a dual behavior: some 
samples displayed an intense and high MCM5 nuclear 
staining, whereas some others a much lesser one, with only 
a cytoplasmic signal. In FTCs, nuclear staining was lesser 
intense and frequent, with a predominant cytoplasmic 
MCM5 staining. ATCs, instead, showed a marked nuclear 
MCM5 localization. No significant differences were observed 
in terms of MCM5 nuclear or cytoplasmic staining intensity 
among different areas of each tumor. Quantification of 
the nuclear immunohistochemical signal was obtained by 
computing the percentage of cell positivity and intensity of 
signal (Fig. 5B). As cytoplasmic MCM5 protein represents the 
inactive MCM5 isoform (Abe et al. 2012), the strong nuclear 
staining observed in all ATCs and several PTCs would indicate 
its hyperactivation. Finally, we measured the expression of 
Mcm5 in four primary ATCs developed by [Pten, Tp53]thyr–/– 
mice (Antico Arciuch et al. 2011). In agreement with the 
human data, Mcm5 was found significantly overexpressed 
in mouse ATC, compared with normal thyroids (Fig. 5C), 
whereas its expression was not altered in FTCs developed by 
Ptenthyr–/– mice (data not shown).
Discussion
The cross talk between genomic and epigenomic 
elements in driving generation and progression of both 
Table 1 Top 20 most downregulated and upregulated genes.
Downregulated genes Upregulated genes
Gene
Log2 (fold_change)
Gene
Log2 (fold_change)
FRO SW1736 FRO SW1736
E2F8 –8.18691 –3.32852 HIST2H2BE 5.45681 6.36269
IL7R –7.92256 –4.28496 EFR3B 5.45085 2.31549
SCG5 –7.07872 –5.36462 HIST1H2BJ 5.41635 4.29568
MFAP2 –6.55018 –4.00946 HIST1H2BC 4.91188 3.90626
KLF17 –5.87194 –2.54046 AQP3 4.82547 5.53788
HAS2 –5.61592 –2.59963 KCNJ2-AS1 4.77102 2.57414
SP140 –5.51289 –2.76406 HIST1H2BD 4.76918 7.37894
SFTA1P –4.86488 –2.30007 HIST1H1C 4.65229 4.36823
APOL3 –4.76234 –3.04492 MSS51 4.53001 4.03264
UHRF1 –4.58863 –2.45864 PROCA1 4.31851 2.40037
ELFN2 –4.56104 –2.07491 RNFT2 4.20444 2.75534
SLC38A5 –4.50203 –3.75806 ARHGAP4 4.14859 2.29762
WDR76 –4.50144 –3.32284 ALS2CR12 4.07061 5.36388
SEMA6B –4.46547 –2.00721 CLU 4.06906 3.93869
STAP2 –4.43699 –3.34008 HIST1H2AC 3.98232 4.03878
RFX8 –4.42127 –3.66572 BFSP1 3.77102 2.63104
FMNL1 –4.42127 –2.04374 ITPR1 3.6183 7.03299
GINS2 –4.3919 –2.49012 FAM222A 3.3286 2.436
HTR1D –4.32174 –3.30238 TLL2 3.24364 2.56248
MCM5 –4.27584 –3.20364 TM7SF2 3.20111 7.24837
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hematologic malignancies and solid tumors has been 
extensively highlighted (Martín-Subero et al. 2013). 
Among epigenetic anticancer drugs, those targeting BET 
proteins have recently emerged as promising therapeutics 
in a remarkable range of diseases (Shi & Vakoc 2014, 
Wee et al. 2014). ATC is the most aggressive thyroid 
cancer subtype and it does not significantly respond to 
any therapy. In order to find new strategies to treat this 
aggressive thyroid cancer subtype, we investigated BETis 
target genes in ATC cell lines. As expected, human ATC 
cell lines FRO and SW1736, treated with three different 
BETis, displayed a decrease in cell viability associated with 
an increase in cell death phenomena. These data were also 
been confirmed in a third ATC cell line (Supplementary 
Fig.  3). In our experimental model, BET inhibition 
triggers a multitarget cascade resulting in substantial 
biological effects, as demonstrated by RNA-seq data. The 
identification of genes mediating BETis antiproliferative 
effect could provide innovative therapeutic targets. 
Among hundreds of deregulated genes after BET 
inhibition, a large fraction belongs to the regulators of cell 
cycle and apoptosis, that is, E2F family members, CDKs 
and CDK inhibitors, and other TP53 pathway-related 
elements (Møller 2003, Smallridge et al. 2009). These 
data are similar to those previously published for study 
in medulloblastoma and metastatic melanoma (Henssen 
et al. 2013, Segura et al. 2013). All these findings 
corroborate the hypothesis that BETis disrupt cell cycle 
control, driving G0/G1 arrest and inducing cell death, by 
acting on multiple targets. Ott and coworkers observed 
that JQ1 treatment decrease the expression of IL7R in 
leukemic cell lines, at both mRNA and protein levels 
(Ott et al. 2012). In anaplastic thyroid cell lines, a 24 h 
JQ1 treatment exhibited a significant downregulation of 
IL7R mRNA levels, but this reduction was not confirmed 
by analyzing protein levels (Supplementary Fig.  5). We 
would like to stress that endogenous IL7R protein is 
not so abundant in these two cell lines; therefore, the 
misregulation of a protein involved during lymphocyte 
development seems not to perform a substantial role in 
JQ1 effects in thyroid cancer cells. Our data, instead, show 
at least a ten-fold downregulation of MCM5 expression 
in JQ1-treated cells, suggesting a critical role of this 
protein in the molecular cascade triggered by BETis. As 
confirmation, MCM5 proved to be a direct target of BRD4, 
as highlighted in the ChIP-qPCR assay. Moreover, MCM5 
overexpression moderately attenuated FRO and SW1736 
JQ1 sensitivity, in terms of cell viability, as shown in the 
rescue experiment (Fig. 4F). This mild effect is reasonably 
due to the multitarget activity of epigenetic drugs, which 
act simultaneously on a wide range of pathways, as shown 
in our RNA-seq analysis. Accordingly to our data, poor 
rescue effects have been obtained for other targets of 
BETis (Lockwood et al. 2012, Bandopadhayay et al. 2014).
MCM5 belongs to the minichromosome maintenance 
complex, which includes elements of the pre-replicative 
complex that are essential for DNA replication (Noseda & 
Karsan 2006). MCM proteins are considered as licensing 
Figure 5
MCM5 expression in thyroid tumors. (A) 
Representative images of MCM5 expression in 
NTs, FAs, PTCs, FTCs, and ATCs. (B) Quantitation 
of MCM5 expression in normal and neoplastic 
thyroid tissues. Quantitation was obtained by 
using the IHC score, calculated as described in 
Materials and methods section. (C) Mcm5 
expression was evaluated by qPCR in control 
thyroids from wild-type mice and primary ATCs 
from [Pten, Tp53]thyr–/– mice. All samples were run 
in triplicate. Wild-type (WT) expression was set at 
1.0 and mRNA levels are expressed as relative 
expression values. Results are shown as 
mean ± s.d. *P < 0.05, **P < 0.01, ****P < 0.0001 by 
ANOVA test.
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components for the S-phase initiation. MCMs oscillate 
between nuclear and cytoplasmic localizations (Madine 
et al. 2000). Nuclear MCMs associate with DNA during G1 
and early S-phase, allowing the control of replication origin 
firing, in order to restrict the chromosome replication to 
only one round per cell cycle (Romanowski & Madine 
1997). MCMs are restricted, instead, to cytoplasm during 
G2/M-phase in order to prevent re-replication phenomena 
(Laskey 2005). Recently, components of the MCM family 
have been described as aberrantly expressed in many 
malignancies, including thyroid carcinomas (Giaginis et al. 
2010). In agreement with these findings and corroborating 
our in vitro and in vivo results, MCM5 immunostaining 
demonstrated that ATCs contained more MCM5-positive 
cells than did normal thyroid gland (Fig. 5).
Several studies have demonstrated that the expression 
of MCM5 is controlled by different pathways (Guida 
et al. 2005, Laskey 2005, Noseda & Karsan 2006, Abe et al. 
2012). Fig. 6 summarizes major players controlling MCM5 
gene expression, as well as their functional interactions. 
By comparing Fig.  6 and Supplementary Table  4, it is 
undeniable that many proteins that upregulate MCM5 
expression are also downregulated by BETis. Interestingly, 
JQ1 reduces the expression of some elements involved 
in the replication fork assembly, thus affecting cell 
cycle mechanisms, in which, in turn, MCM proteins are 
involved. Altogether, this cascade could lead to G0/G1 
arrest (Fig. 1D) and cell death. In conclusion, our findings 
support the hypothesis that MCM5 targeting may be 
regarded as an effective molecular therapy against ATC.
Figure 6 
Biological network related to MCM protein 
function. Network diagram (upper part) showing 
key molecules controlling MCM protein levels. 
White symbols represent proteins whose mRNA 
levels are modulated by BETis in our 
transcriptome analysis (see Supplementary 
Table 4); gray symbols indicate proteins whose 
mRNA levels are not modulated by BETis. Arrows 
indicate functional relationship between proteins 
(delineated in Madine et al. 2000, Guida et al. 
2005, Laskey 2005, Abe et al. 2012). The lower 
part indicates factors cooperating with MCM 
proteins in the replicative fork assembly. All of 
these factors are downregulated by BETis (see 
Supplementary Table 4). Arrowheads show the 
relationship between MCMs and cell cycle phases.
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Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/
ERC-15-0322.
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